Roche Holding AG Stock price Swiss Exchange

Equities

RO

CH0012032113

Pharmaceuticals

Real-time Estimate Cboe Europe 04:26:01 2024-03-28 am EDT 5-day change 1st Jan Change
241.7 CHF +0.71% Intraday chart for Roche Holding AG +1.60% -7.73%
Sales 2024 * 59.59B 65.76B Sales 2025 * 63.24B 69.79B Capitalization 182B 201B
Net income 2024 * 13.07B 14.43B Net income 2025 * 14.56B 16.07B EV / Sales 2024 * 3.28 x
Net Debt 2024 * 13.23B 14.59B Net Debt 2025 * 7.15B 7.89B EV / Sales 2025 * 2.99 x
P/E ratio 2024 *
14 x
P/E ratio 2025 *
12.5 x
Employees 103,605
Yield 2024 *
4.23%
Yield 2025 *
4.4%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day+0.71%
1 week+1.60%
Current month-1.71%
1 month-2.19%
3 months-6.58%
6 months-9.53%
Current year-7.73%
More quotes
1 week
235.80
Extreme 235.8
241.20
1 month
235.80
Extreme 235.8
259.60
Current year
235.80
Extreme 235.8
277.40
1 year
235.80
Extreme 235.8
318.00
3 years
235.80
Extreme 235.8
439.20
5 years
235.80
Extreme 235.8
439.20
10 years
209.40
Extreme 209.4
439.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Date Price Change Volume
24-03-28 241.2 +0.50% 3 790
24-03-27 240 +0.08% 30,138
24-03-26 239.8 +0.59% 30,077
24-03-25 238.4 +0.59% 24,644
24-03-22 237 -0.17% 27,179

Delayed Quote Swiss Exchange, March 28, 2024 at 04:11 am EDT

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
226.8 CHF
Average target price
281.3 CHF
Spread / Average Target
+24.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Roche Holding AG
  4. Stock Roche Holding AG - Swiss Exchange